← Evidence map

ArticleCancer medicine2022

Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States.

Rajwanth Veluswamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2022

2023

this papercites it

Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States. | OpenQuestion